Michael Lichtenauer1, Peter Jirak2, Bernhard Wernly2, Vera Paar2, Ilonka Rohm3, Christian Jung4, Christiana Schernthaner2, Johannes Kraus2, Lukas J Motloch2, Atilla Yilmaz5, Uta C Hoppe2, P Christian Schulze3, Daniel Kretzschmar3, Rudin Pistulli3. 1. Clinic of Internal Medicine II, Department of Cardiology, Paracelsus Medical University of Salzburg, Austria. Electronic address: michael.lichtenauer@chello.at. 2. Clinic of Internal Medicine II, Department of Cardiology, Paracelsus Medical University of Salzburg, Austria. 3. Universitätsherzzentrum Thüringen, Clinic of Internal Medicine I, Department of Cardiology, Friedrich Schiller University Jena, Germany. 4. Division of Cardiology, Pulmonology, and Vascular Medicine, Medical Faculty, University Duesseldorf, Germany. 5. Clinic of Internal Medicine II, Elisabeth Klinikum Schmalkalden, Germany.
Abstract
BACKGROUND: Heart failure (HF) with reduced ejection fraction remains a major therapeutic challenge. The aim of this study was to investigate the role of novel cardiovascular biomarkers, i.e. soluble suppression of tumorigenicity (sST2), growth-differentiation factor-15 (GDF-15), soluble urokinase plasminogen activator receptor (suPAR) and heart-type fatty acid binding protein (H-FABP) in patients with ischaemic (ICM) or dilative cardiomyopathy (DCM). MATERIALS AND METHODS: A total of 200 patients were enrolled in this study: 65 were diagnosed with DCM and 59 patients suffering from ICM were included. 76 patients without coronary artery disease or signs of heart failure were included as controls. Plasma samples of all patients were analyzed by use of ELISA. RESULTS: Levels of sST2, suPAR and H-FABP were significantly higher in ICM and DCM patients compared to the control group (p<0.0001). However, there were no significant differences between ICM and DCM in biomarker levels. Ejection fraction correlated inversely with cardiac biomarkers (sST2 p<0.0001, GDF-15 p=0.0394, suPAR p=0.0029, H-FABP p<0.0001). Similarly, CRP levels also showed a positive correlation with cardiac biomarkers. Renal insufficiency (p<0.0001) and diabetes (sST2 p=0.0021, GDF-15 p=0.0055, suPAR p=0.0339, H-FABP p=0.0010) were significantly associated with a rise in cardiac biomarkers. CONCLUSION: Novel cardiovascular biomarkers such as ST2, GDF-15, uPAR and H-FABP could offer a great potential for more precise diagnostic in ICM and DCM patients. H-FABP was the most promising marker in our study, followed by sST2, uPAR and GDF-15. Additional prospective studies will be necessary to further evaluate the potential clinical benefits in routine treatment of HF.
BACKGROUND:Heart failure (HF) with reduced ejection fraction remains a major therapeutic challenge. The aim of this study was to investigate the role of novel cardiovascular biomarkers, i.e. soluble suppression of tumorigenicity (sST2), growth-differentiation factor-15 (GDF-15), soluble urokinase plasminogen activator receptor (suPAR) and heart-type fatty acid binding protein (H-FABP) in patients with ischaemic (ICM) or dilative cardiomyopathy (DCM). MATERIALS AND METHODS: A total of 200 patients were enrolled in this study: 65 were diagnosed with DCM and 59 patients suffering from ICM were included. 76 patients without coronary artery disease or signs of heart failure were included as controls. Plasma samples of all patients were analyzed by use of ELISA. RESULTS: Levels of sST2, suPAR and H-FABP were significantly higher in ICM and DCMpatients compared to the control group (p<0.0001). However, there were no significant differences between ICM and DCM in biomarker levels. Ejection fraction correlated inversely with cardiac biomarkers (sST2 p<0.0001, GDF-15 p=0.0394, suPAR p=0.0029, H-FABP p<0.0001). Similarly, CRP levels also showed a positive correlation with cardiac biomarkers. Renal insufficiency (p<0.0001) and diabetes (sST2 p=0.0021, GDF-15 p=0.0055, suPAR p=0.0339, H-FABP p=0.0010) were significantly associated with a rise in cardiac biomarkers. CONCLUSION: Novel cardiovascular biomarkers such as ST2, GDF-15, uPAR and H-FABP could offer a great potential for more precise diagnostic in ICM and DCMpatients. H-FABP was the most promising marker in our study, followed by sST2, uPAR and GDF-15. Additional prospective studies will be necessary to further evaluate the potential clinical benefits in routine treatment of HF.
Authors: Harsh Goel; Joshua Melot; Matthew D Krinock; Ashish Kumar; Sunil K Nadar; Gregory Y H Lip Journal: Ann Med Date: 2020-08-04 Impact factor: 4.709
Authors: Peter Jirak; Rudin Pistulli; Michael Lichtenauer; Bernhard Wernly; Vera Paar; Lukas J Motloch; Richard Rezar; Christian Jung; Uta C Hoppe; P Christian Schulze; Daniel Kretzschmar; Rüdiger C Braun-Dullaeus; Tarek Bekfani Journal: J Clin Med Date: 2020-04-15 Impact factor: 4.241
Authors: Peter Jirak; Dzeneta Fejzic; Vera Paar; Bernhard Wernly; Rudin Pistulli; Ilonka Rohm; Christian Jung; Uta C Hoppe; P Christian Schulze; Michael Lichtenauer; Atilla Yilmaz; Daniel Kretzschmar Journal: Acta Pharmacol Sin Date: 2017-12-14 Impact factor: 6.150
Authors: Michael Lichtenauer; Tristan Pichler; Sarah Eder; Moritz Mirna; Theresa Magnes; Bernhard Wernly; Vera Paar; Christian Jung; Erika Prinz; Rainald Seitelberger; Uta C Hoppe Journal: ESC Heart Fail Date: 2019-01-08
Authors: Richard Rezar; Peter Jirak; Martha Gschwandtner; Rupert Derler; Thomas K Felder; Michael Haslinger; Kristen Kopp; Clemens Seelmaier; Christina Granitz; Uta C Hoppe; Michael Lichtenauer Journal: J Clin Med Date: 2020-01-07 Impact factor: 4.241
Authors: Heinz-Peter Schultheiss; DeLisa Fairweather; Alida L P Caforio; Felicitas Escher; Ray E Hershberger; Steven E Lipshultz; Peter P Liu; Akira Matsumori; Andrea Mazzanti; John McMurray; Silvia G Priori Journal: Nat Rev Dis Primers Date: 2019-05-09 Impact factor: 65.038
Authors: Dimitrios Velissaris; Nicholas Zareifopoulos; Ioanna Koniari; Vasilios Karamouzos; Dimitris Bousis; Andreas Gerakaris; Christina Platanaki; Nicholas Kounis Journal: J Clin Med Res Date: 2021-03-19
Authors: Albert Topf; Moritz Mirna; Vera Paar; Lukas J Motloch; Janine Grueninger; Christiane Dienhart; Paul C Schulze; Mathias C Brandt; Robert Larbig; Uta C Hoppe; Daniel Kretzschmar; Michael Lichtenauer Journal: Clin Res Cardiol Date: 2021-11-02 Impact factor: 5.460